90 related articles for article (PubMed ID: 20863351)
1. Once-daily memantine: pharmacokinetic and clinical considerations.
Gomolin IH; Smith C; Jeitner TM
J Am Geriatr Soc; 2010 Sep; 58(9):1812-3. PubMed ID: 20863351
[No Abstract] [Full Text] [Related]
2. Memantine standard tablet and extended-release dosing considerations: a pharmacokinetic analysis.
Lam S; Smith C; Gomolin IH
J Am Geriatr Soc; 2015 Feb; 63(2):383-4. PubMed ID: 25688611
[No Abstract] [Full Text] [Related]
3. Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease.
Jones RW; Bayer A; Inglis F; Barker A; Phul R
Int J Geriatr Psychiatry; 2007 Mar; 22(3):258-62. PubMed ID: 17243195
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
Periclou A; Ventura D; Rao N; Abramowitz W
Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
[TBL] [Abstract][Full Text] [Related]
5. Memantine for treatment of moderate to severe Alzheimer's disease.
Perras C
Issues Emerg Health Technol; 2005 Mar; (64):1-4. PubMed ID: 15762015
[TBL] [Abstract][Full Text] [Related]
6. Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease.
Bassil N; Thaipisuttikul P; Grossberg GT
Expert Opin Pharmacother; 2010 Jul; 11(10):1765-71. PubMed ID: 20540654
[TBL] [Abstract][Full Text] [Related]
7. [Anti-dementia therapy pays at every stage of the disease. Patients with Alzheimer's disease stay all-day fit longer].
MMW Fortschr Med; 2003 May; 145 Suppl 2():113. PubMed ID: 14579507
[No Abstract] [Full Text] [Related]
8. Different conclusions about memantine.
Lexchin J
Can Fam Physician; 2007 Mar; 53(3):403-4; author reply 404. PubMed ID: 17872671
[No Abstract] [Full Text] [Related]
9. Memantine dosing in patients with dementia.
Dolder C; Nelson M; McKinsey J
Am J Geriatr Psychiatry; 2009 Feb; 17(2):170-3. PubMed ID: 19155749
[TBL] [Abstract][Full Text] [Related]
10. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.
Farlow MR; Alva G; Meng X; Olin JT
Curr Med Res Opin; 2010 Feb; 26(2):263-9. PubMed ID: 19929593
[TBL] [Abstract][Full Text] [Related]
11. [Memantine in the pharmacologic treatment of moderately severe to severe Alzheimer's disease in Spain (MEMORY study)].
Agüera-Ortiz LF;
Rev Neurol; 2010 Nov; 51(9):525-34. PubMed ID: 20979032
[TBL] [Abstract][Full Text] [Related]
12. Predictors of adherence among Alzheimer's disease patients receiving oral therapy.
Borah B; Sacco P; Zarotsky V
Curr Med Res Opin; 2010 Aug; 26(8):1957-65. PubMed ID: 20569067
[TBL] [Abstract][Full Text] [Related]
13. Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study.
Rao N; Chou T; Ventura D; Abramowitz W
Clin Ther; 2005 Oct; 27(10):1596-606. PubMed ID: 16330295
[TBL] [Abstract][Full Text] [Related]
14. Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil.
Periclou AP; Ventura D; Sherman T; Rao N; Abramowitz WT
Ann Pharmacother; 2004 Sep; 38(9):1389-94. PubMed ID: 15266045
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of Memantine after a Single and Multiple Dose of Oral and Patch Administration in Rats.
Lee SH; Kim SH; Noh YH; Choi BM; Noh GJ; Park WD; Kim EJ; Cho IH; Bae CS
Basic Clin Pharmacol Toxicol; 2016 Feb; 118(2):122-7. PubMed ID: 26310825
[TBL] [Abstract][Full Text] [Related]
16. A pharmaceutical answer to nonadherence: Once weekly oral memantine for Alzheimer's disease.
Kanasty R; Low S; Bhise N; Yang J; Peeke E; Schwarz M; Wright J; Carter B; Moorthy S; Grant T; DeBenedictis B; Bishoff M; Simses C; Bellinger AM
J Control Release; 2019 Jun; 303():34-41. PubMed ID: 30928488
[TBL] [Abstract][Full Text] [Related]
17. The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis.
Livingston G; Katona C
Int J Geriatr Psychiatry; 2004 Oct; 19(10):919-25. PubMed ID: 15449303
[TBL] [Abstract][Full Text] [Related]
18. [New options for the pharmacotherapy of Alzheimer's disease after the registration of memantine?].
Frölich L; Schmitt B; Calabrese P; Diener H; Förstl H; Gertz HJ; Hallauer JF; Hampel H; Ihl R; Rieke K; Riepe M; Supprian T
Dtsch Med Wochenschr; 2005 Feb; 130(8):408-12. PubMed ID: 15717252
[No Abstract] [Full Text] [Related]
19. Antipsychotic dose-sparing effect with addition of memantine.
Sleeper RB
Ann Pharmacother; 2005 Sep; 39(9):1573-6. PubMed ID: 16076907
[TBL] [Abstract][Full Text] [Related]
20. Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects.
Yao C; Raoufinia A; Gold M; Nye JS; Ramael S; Padmanabhan M; Walschap Y; Verhaeghe T; Zhao Q
J Clin Pharmacol; 2005 May; 45(5):519-28. PubMed ID: 15831775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
